JULY 16, 2019
Outlook Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
APRIL 1, 2019
Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010
More >

Outlook Therapeutics…

…is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, for various ophthalmic indications..


ONS-5010 is a proprietary ophthalmic formulation of bevacizumab to be administered as an intravitreal injection for the treatment of wet AMD and other retina diseases.